Chronic rhinosinusitis and eosinophils: do macrolides have an effect?

Area of Science:

• Immunology
• Pharmacology
• Respiratory Medicine

Background:

• Chronic airway inflammation involves key mediators like eosinophils.
• Long-term, low-dose macrolide antibiotics possess anti-inflammatory properties distinct from their antimicrobial effects.
• Macrolides are explored for their potential to modulate chronic inflammatory conditions.

Purpose of the Study:

• To review the impact of macrolides on eosinophilic inflammation in chronic airway diseases.
• To assess the role of macrolides in conditions like chronic rhinosinusitis and asthma.
• To evaluate the clinical relevance of macrolide therapy in eosinophil-driven inflammation.

Main Methods:

• Analysis of in vitro studies investigating macrolide effects on eosinophil apoptosis and cytokine production.
• Review of in vivo studies examining eosinophil counts and activity in animal models and human subjects.
• Evaluation of clinical data on macrolide treatment response in patients with varying inflammatory profiles.

Main Results:

• In vitro data suggest macrolides can increase eosinophil apoptosis and decrease chemotactic cytokine production.
• In vivo studies indicate a reduction in eosinophil count and activity in asthma and chronic rhinosinusitis models.
• Clinical response to macrolides may be less favorable in atopic individuals with prominent eosinophilic inflammation.

Conclusions:

• Current evidence for macrolides influencing eosinophilic inflammation is limited compared to neutrophilic inflammation.
• Patients with significant eosinophilic inflammation might be less responsive to macrolide therapy.
• Further in vitro and clinical research is necessary to fully elucidate macrolide effects on eosinophilic inflammation.